Holen Sie sich die Stockscreener-App
231.32
0.45%
-1.51
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$232.83
Offen:
$231.48
24-Stunden-Volumen:
167.57K
Relative Volume:
0.03
Marktkapitalisierung:
$408.83B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
110.08
EPS:
2.1013
Netto-Cashflow:
$18.24B
1W Leistung:
-5.16%
1M Leistung:
+10.48%
6M Leistung:
+31.94%
1J Leistung:
+20.09%
1-Tages-Spanne:
$231.03
$232.16
1-Wochen-Bereich:
$227.59
$242.67
52-Wochen-Spanne:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
231.43 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
847.54 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.31 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
132.86 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.63 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Dohj LLC Acquires 1,335 Shares of AbbVie Inc. $ABBV - MarketBeat
Why AbbVie and Johnson & Johnson Could Outperform Pfizer - MarketBeat
WoodTrust Financial Corp Raises Stake in AbbVie Inc. $ABBV - MarketBeat
Winthrop Advisory Group LLC Has $845,000 Position in AbbVie Inc. $ABBV - MarketBeat
Citizens National Bank Trust Department Boosts Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Raub Brock Capital Management LP's 10th Largest Position - MarketBeat
AbbVie Inc. $ABBV Stock Holdings Cut by Louisiana State Employees Retirement System - MarketBeat
Friedenthal Financial Acquires 1,261 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Holdings Cut by Kingswood Wealth Advisors LLC - MarketBeat
Why AbbVie Stock Soared in September - Nasdaq
AbbVie (NYSE:ABBV) Stock Price Up 1.4%What's Next? - MarketBeat
Spinal Cord Injury Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen - Barchart.com
KLP Kapitalforvaltning AS Buys 19,100 Shares of AbbVie Inc. $ABBV - MarketBeat
Hardy Reed LLC Sells 1,802 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Position Decreased by High Note Wealth LLC - MarketBeat
Shell Asset Management Co. Purchases 15,438 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie 2025: Moving on - PharmaLive
SteelPeak Wealth LLC Boosts Stake in AbbVie Inc. $ABBV - MarketBeat
Presbyopia Market Analysis and Forecast Report 2025-2035 Featuring AbbVie, Eyenovia, Entod Pharma, L - PharmiWeb.com
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor - Investing News Network
AbbVie's (ABBV) Botox Study Shows Promising Results for Essentia - GuruFocus
AbbVie's Botox Shows Improvement In Movement Disorder Study - inkl
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk - The Globe and Mail
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week? - Yahoo Finance
AbbVie (ABBV) Achieves Positive Results in Phase 2 Trial for Essential Tremor - GuruFocus
AbbVie succeeds in mid-stage study of Botox for essential tremor - Seeking Alpha
AbbVie (ABBV) Positioned Amid Gilead's Patent Extension for Biktarvy - GuruFocus
AbbVie Says Botox Met Primary Endpoint in Phase 2 Upper Limb Essential Tremor Trial - MarketScreener
AbbVie reports positive results in essential tremor treatment trial By Investing.com - Investing.com Canada
AbbVie reports positive results in essential tremor treatment trial - Investing.com
AbbVie Says Phase 2 ELATE Trial Met Primary Endpoint For BOTOX To Treat Upper Limb Essential Tremor - Nasdaq
AbbVie announces positive phase 2 Elate trial results for onabotulinumtoxinA (Botox®) in treating upper limb essential tremor - MarketScreener
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor - Stock Titan
AbbVie expansion win for the city - Spectrum News
Prime Capital Investment Advisors LLC Sells 30,567 Shares of AbbVie Inc. $ABBV - MarketBeat
Comprehensive Financial Consultants Institutional Inc. Grows Stake in AbbVie Inc. $ABBV - MarketBeat
Belpointe Asset Management LLC Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Cullinan Associates Inc. Cuts Holdings in AbbVie Inc. $ABBV - MarketBeat
Appleton Partners Inc. MA Purchases 2,010 Shares of AbbVie Inc. $ABBV - MarketBeat
Chung Wu Investment Group LLC Sells 2,360 Shares of AbbVie Inc. $ABBV - MarketBeat
Valeo Financial Advisors LLC Purchases 2,636 Shares of AbbVie Inc. $ABBV - MarketBeat
DAVENPORT & Co LLC Acquires 4,968 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Holdings Raised by Grimes & Company Inc. - MarketBeat
Merit Financial Group LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Three Bridge Wealth Advisors LLC Makes New $495,000 Investment in AbbVie Inc. $ABBV - MarketBeat
Global Assets Advisory LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Can AbbVie Inc. stock outperform in 2025 bull marketQuarterly Performance Summary & Daily Volume Surge Signals - newser.com
Why AbbVie Inc. stock is in analyst buy zoneTrade Entry Summary & Technical Pattern Alert System - newser.com
AbbVie Inc. $ABBV Shares Acquired by Simplicity Wealth LLC - MarketBeat
Wealthcare Advisory Partners LLC Increases Holdings in AbbVie Inc. $ABBV - MarketBeat
Hill Island Financial LLC Invests $209,000 in AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):